Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
These data were presented at the 61st European Renal Association Congress (ERA24) being held in Stockholm.
- These data were presented at the 61st European Renal Association Congress (ERA24) being held in Stockholm.
- “For the first time in this field, we presented 72-week data from our Phase 2b ORIGIN trial showing stable kidney function over the duration of treatment.
- In addition, we presented data showing that atacicept leads to hematuria resolution in significantly more patients compared with placebo.
- The evolving atacicept data package supports our belief that atacicept may offer comprehensive disease modification to patients with IgAN,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics.